A functional drug delivery platform for targeting and imaging cancer cells based on Pluronic F127
Source abstract
Abstract
Functional polymeric micelles play an important role in the efficient delivery of therapeutic drugs into tumours. In this study, a functional drug delivery platform with ligands for targeting and fluorescent imaging was designed based on Pluronic F127 (PF127). Using folic acid (FA) and fluorescein isothiocyanate (FITC) to chemically conjugate with PF127, two functional polymers, Pluronic F127-FA (PF127-FA) and Pluronic F127-FITC (PF127-FITC), were synthesized. Solasodine-loaded micelles were then prepared via the thin-film hydration method. By employing A549 and HeLa cells, the results of in vitro cell assays performed using confocal laser scanning microscopy and flow cytometry suggested that the proposed micelles could provide the desired specific targeting and fluorescent imaging functions. In addition, the results of in vitro cytotoxicity experiments showed that the growth inhibition rates of A549 and HeLa cells treated with solasodine-loaded micelles were remarkably higher than those of cells treated with free solasodine. Solasodine-loaded micelles exhibited a more distinct inhibitory effect against HeLa cells than against A549 cells. Thus, an effective drug delivery system for targeting and imaging cancer cells was developed.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. 10.1007/s10059-011-0051-510.1007/s10059-011-0051-5 ↗
2. 10.1002/adma.20110014010.1002/adma.201100140 ↗
3. 10.1016/j.ejpb.2006.11.00910.1016/j.ejpb.2006.11.009 ↗
4. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
5. 10.1016/j.drudis.2014.06.02010.1016/j.drudis.2014.06.020 ↗
6. 10.1039/c2cs15344k10.1039/c2cs15344k ↗
7. 10.1021/bm400121q10.1021/bm400121q ↗
8. 10.1021/bc100546s10.1021/bc100546s ↗
9. 10.1158/1078-0432.CCR-08-015910.1158/1078-0432.CCR-08-0159 ↗
10. 10.1016/j.ijpharm.2014.04.00810.1016/j.ijpharm.2014.04.008 ↗
11. 10.1021/jm401907z10.1021/jm401907z ↗
12. 10.1016/j.ejmech.2013.11.04010.1016/j.ejmech.2013.11.040 ↗
13. 10.1021/cn400182z10.1021/cn400182z ↗
14. 10.1002/(ISSN)1616-519510.1002/(ISSN)1616-5195 ↗
15. 10.1021/jp104711q10.1021/jp104711q ↗
16. 10.1016/S0065-2571(00)00013-310.1016/S0065-2571(00)00013-3 ↗
17. 10.1002/jso.v105.710.1002/jso.v105.7 ↗
18. 10.1016/j.ijpharm.2003.09.05010.1016/j.ijpharm.2003.09.050 ↗
19. 10.1016/j.addr.2010.04.00910.1016/j.addr.2010.04.009 ↗
20. 10.1615/CritRevTherDrugCarrierSyst.v19.i110.1615/CritRevTherDrugCarrierSyst.v19.i1 ↗
21. 10.1016/j.ejpb.2007.03.02210.1016/j.ejpb.2007.03.022 ↗
22. 10.1016/j.jconrel.2008.04.01310.1016/j.jconrel.2008.04.013 ↗
23. Harrington KJ · Clin. Cancer Res · 2000 · 6 · 2528
24. 10.1007/s00280-007-0449-010.1007/s00280-007-0449-0 ↗
25. 10.1007/s00396-014-3183-210.1007/s00396-014-3183-2 ↗
26. 10.1007/s12033-008-9045-810.1007/s12033-008-9045-8 ↗
27. 10.1007/s10637-010-9399-110.1007/s10637-010-9399-1 ↗
28. Danson S · Br. J. Cancer · 2004 · 90 · 208510.1038/sj.bjc.6601856 ↗
29. 10.1038/sj.gt.330118910.1038/sj.gt.3301189 ↗
30. 10.1002/(ISSN)1521-225410.1002/(ISSN)1521-2254 ↗
31. 10.1097/00000658-198201001-0001010.1097/00000658-198201001-00010 ↗
32. Adams-Graves P · Blood · 1997 · 90 · 204110.1182/blood.V90.5.2041 ↗
33. 10.1002/(ISSN)1520-601710.1002/(ISSN)1520-6017 ↗
34. 10.1080/1388020070153869010.1080/13880200701538690 ↗
35. 10.4236/mc.2013.2200510.4236/mc.2013.22005 ↗
36. 10.1021/jf200439q10.1021/jf200439q ↗
37. 10.1021/ma981455010.1021/ma9814550 ↗
38. 10.1016/j.biomaterials.2010.12.03910.1016/j.biomaterials.2010.12.039 ↗
39. 10.1016/j.msec.2013.02.03610.1016/j.msec.2013.02.036 ↗
40. 10.1016/j.biomaterials.2009.06.00410.1016/j.biomaterials.2009.06.004 ↗
41. 10.1002/(ISSN)1520-601710.1002/(ISSN)1520-6017 ↗
42. 10.1021/mp500187310.1021/mp5001873 ↗